Hikma Pharmaceuticals Plc Annual Information Update (7302J)
April 09 2015 - 6:16AM
UK Regulatory
TIDMHIK
RNS Number : 7302J
Hikma Pharmaceuticals Plc
09 April 2015
Hikma Pharmaceuticals PLC
Annual Information Update
London, 9 April 2015. In accordance with Prospectus Rule 5.2,
Hikma Pharmaceuticals PLC ("Hikma" or "the Company") (LSE: HIK)
sets out below a summary of the information which has been
published or made available to the public over the period. In
accordance with Prospectus Rule 5.2.7, it is acknowledged that
whilst the information referred to in this update was up to date at
the time of publication, such disclosures may, at any time, become
out of date due to changing circumstances.
Stock Exchange Announcements
Announcements made by the Company via RNS, a Regulatory
Information Service, may be viewed and downloaded from the
Company's market news section on the London Stock Exchange website
at
(http://www.londonstockexchange.com/prices-and-news/stocks/stocks-and-prices.htm)
or from the press releases page on the Company's website at
(http://www.hikma.com/investorrelations/rns/). The Stock Exchange
announcements made during the period were:
Date Headline
09/04/2015 Annual Financial Report
------------------------------------------
Hikma Prices debut $500 million five-year
01/04/2015 eurobond
------------------------------------------
31/03/2015 Stabilisation Notice
------------------------------------------
19/03/2015 Fixed income investor meetings
------------------------------------------
13/03/2015 Director/PDMR Shareholding
------------------------------------------
11/03/2015 Holding(s) in Company
------------------------------------------
11/03/2015 Final Results
------------------------------------------
23/01/2015 Director Declaration
------------------------------------------
21/01/2015 Notification of major interest in shares
------------------------------------------
15/01/2015 Blocklisting Interim Review
------------------------------------------
12/01/2015 Hikma to launch colchicine 0.6mg capsules
------------------------------------------
07/01/2015 Total Voting Rights
------------------------------------------
12/11/2014 Director/PDMR Shareholding
------------------------------------------
11/11/2014 Total Voting Rights
------------------------------------------
07/11/2014 Notification of major interest in shares
------------------------------------------
06/11/2014 Directorate Change
------------------------------------------
06/11/2014 Interim Management Statement
------------------------------------------
Hikma announces receipt of Warning Letter
24/10/2014 from FDA
------------------------------------------
20/10/2014 Director/PDMR Shareholding
------------------------------------------
10/10/2014 Statement re Colchicine
------------------------------------------
10/10/2014 Director/PDMR Shareholding
------------------------------------------
06/10/2014 Blocklisting Interim Review
------------------------------------------
06/10/2014 Total Voting Rights
------------------------------------------
30/09/2014 Regulatory Approval Colchicine
------------------------------------------
17/09/2014 Acquisition
------------------------------------------
20/08/2014 Dividend Declaration
------------------------------------------
20/08/2014 Interim Results
------------------------------------------
07/08/2014 Notice of Interim Results Announcement
------------------------------------------
28/07/2014 Director/PDMR Shareholding
------------------------------------------
24/07/2014 Acquisition
------------------------------------------
15/07/2014 Acquisition
------------------------------------------
14/07/2014 Total Voting Rights
------------------------------------------
27/06/2014 Director/PDMR Shareholding
------------------------------------------
23/06/2014 Director/PDMR Shareholding
------------------------------------------
11/06/2014 Director/PDMR Shareholding
------------------------------------------
10/06/2014 Total Voting Rights
------------------------------------------
29/05/2014 Director/PDMR Shareholding
------------------------------------------
29/05/2014 Director/PDMR Shareholding
------------------------------------------
28/05/2014 Acquisition
------------------------------------------
27/05/2014 Director/PDMR Shareholding
------------------------------------------
15/05/2014 Results of AGM
------------------------------------------
15/04/2014 Interim Management Statement
------------------------------------------
06/05/2014 Director/PDMR Shareholding
------------------------------------------
17/04/2014 Annual Information Update
------------------------------------------
All of the above announcements were also made by the Company via
the Nasdaq Dubai stock exchange CANDI system. These announcements
may be viewed and downloaded from the Nasdaq Dubai website
(www.candi.nasdaq.com).
Documents filed with the Financial Services Authority
The Company has filed the following documents with the Financial
Services Authority ("FSA") visa the National Storage Mechanism over
the previous 12 months. These documents are available at
http://www.hemscott.com/nsm.do or at the Company's registered
office.
Date Document
09/04/2015 Annual Report and Accounts 2014
----------------------------------------
09/04/2015 Notice of 2015 Annual General Meeting
----------------------------------------
09/04/2015 Proxy forms for the 2015 Annual General
Meeting
----------------------------------------
10/04/2014 Annual Report and Accounts 2013
----------------------------------------
10/04/2014 Notice of 2014 Annual General Meeting
----------------------------------------
10/04/2014 Proxy forms for the 2014 Annual General
Meeting
----------------------------------------
Documents filed with Companies House
The Company submitted filings to the Registrar of Companies in
England and Wales as detailed in the table below.
Date Filed Form Description
07/04/2015 SH01 Statement of Capital GBP 19,887,933.90
--------- ----------------------------------------
12/12/2014 AP01 Director Appointed Dr. Pamela Josephine
Kirby
--------- ----------------------------------------
11/11/2014 SH01 Statement of Capital GBP 19,862,523.90
--------- ----------------------------------------
06/10/2014 SH01 Statement of Capital GBP 19,855,195
--------- ----------------------------------------
08/09/2014 AR01 No Member List
--------- ----------------------------------------
10/06/2014 SH01 Statement of Capital GBP 19,843,04.77
--------- ----------------------------------------
09/06/2014 RES01 Alter Articles 15/05/2014
--------- ----------------------------------------
09/06/2014 MEM/ARTS Articles of Association
--------- ----------------------------------------
21/05/2014 SH04 Treasury Capital GBP 0
--------- ----------------------------------------
20/05/2014 RES01 Alter Articles 15/05/2014
--------- ----------------------------------------
20/05/2014 AA Group of Companies' Accounts made up
to 31/12/13
--------- ----------------------------------------
15/05/2014 AP01 Director Appointed Mr. Patrick Noel
Butler
--------- ----------------------------------------
15/05/2014 TM01 Appointment Terminated, Director Samih
Darwazah
--------- ----------------------------------------
15/05/2014 TM01 Appointment Terminated, Director David
Rowe Ham
--------- ----------------------------------------
23/04/2014 MR01 Registration of a Charge/ Charge Code
055579340003
--------- ----------------------------------------
07/04/2014 SH01 Statement of Capital GBP 19,815,699.70
--------- ----------------------------------------
Copies of all these documents may be obtained from Companies
House, Crown Way, Maindy, Cardiff CF14 3UZ or, if you are a
registered user, they may be viewed and downloaded using Companies
House "Webcheck" at www.companieshouse.gov.uk.
Documents provided to Shareholders
Further Information
Copies of all documents can be obtained from the Company at the
registered office which is located at 13 Hanover Square, London W1S
1HW.
Peter Speirs
Company Secretary
9 April 2015
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary +44 20 7399 2670
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2014, Hikma achieved
revenues of $1,489 million and profit attributable to shareholders
of $299 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AIUBKLFBEZFFBBZ
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024
